BioCryst

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade BioCryst 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BCRX

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. 

CEO
Charles K. Gayer
CEOCharles K. Gayer
Employees
435
Employees435
Headquarters
Durham, North Carolina
HeadquartersDurham, North Carolina
Founded
1986
Founded1986
Employees
435
Employees435

BCRX Key Statistics

Market cap
2.18B
Market cap2.18B
Price-Earnings ratio
-4.83
Price-Earnings ratio-4.83
Dividend yield
Dividend yield
Average volume
4.31M
Average volume4.31M
High today
$8.80
High today$8.80
Low today
$8.50
Low today$8.50
Open price
$8.67
Open price$8.67
Volume
3.71M
Volume3.71M
52 Week high
$11.31
52 Week high$11.31
52 Week low
$6.00
52 Week low$6.00

Stock Snapshot

With a market cap of 2.18B, BioCryst(BCRX) trades at $8.56. The stock has a price-to-earnings ratio of -4.83.

On 2026-05-12, BioCryst(BCRX) stock moved within a range of $8.50 to $8.80. With shares now at $8.56, the stock is trading +0.7% above its intraday low and -2.7% below the session's peak.

Trading activity shows a volume of 3.71M, compared to an average daily volume of 4.31M.

The stock's 52-week range extends from a low of $6.00 to a high of $11.31.

The stock's 52-week range extends from a low of $6.00 to a high of $11.31.

BCRX News

Benzinga 5d
These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) reported upbeat earnings for the first quarter on Wednesday. The company posted quarterly earnings of 14 cents per s...

These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings
TipRanks 5d
BioCryst price target raised to $28 from $25 at Citizens

Citizens analyst Jonathan Wolleben raised the firm’s price target on BioCryst (BCRX) to $28 from $25 and keeps an Outperform rating on the shares. Orladeyo post...

TipRanks 5d
BioCryst Earnings Call: Growth, Pipeline And New Risks

BioCryst Pharmaceuticals ((BCRX)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level dat...

Analyst ratings

100%

of 11 ratings
Buy
100%
Hold
0%
Sell
0%

More BCRX News

Nasdaq 5d
BioCryst Q1 2026 Earnings Transcript

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...

BioCryst Q1 2026 Earnings Transcript
TipRanks 6d
BioCryst Posts Q1 2026 Results, Maintains Growth Outlook

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Simply Wall St 7d
Does BioCryst’s European Navenibart Licensing Deal and Cash Infusion Change The Bull Case For BCRX?

On 4 May 2026, BioCryst Pharmaceuticals announced it had licensed European commercialization rights for its investigational HAE therapy navenibart to an Irish a...

Does BioCryst’s European Navenibart Licensing Deal and Cash Infusion Change The Bull Case For BCRX?

People also own

Based on the portfolios of people who own BCRX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.